IL-7 receptor

Class

Long-acting IL-7 fusion protein (immune reconstitution)

The interleukin-7 receptor (IL-7R) is expressed on developing and mature T lymphocytes and is essential for their survival, proliferation, and homeostatic maintenance. Its natural ligand, IL-7, is produced by stromal and epithelial cells and signals through IL-7R to sustain the peripheral T-cell pool, particularly in states of lymphocyte depletion. The biological rationale for pharmacologically engaging this receptor is to restore or expand T-cell numbers and diversity when the immune system has been depleted, whether by disease, chemotherapy, radiation, or chronic infection. Conditions marked by profound lymphopenia—including certain cancers, severe infections, and immunodeficiencies—are contexts where boosting IL-7 signaling is of therapeutic interest, since restoring T-cell numbers can improve immune surveillance and infection control. A fusion protein approach, in which IL-7 is linked to a stabilizing protein domain, extends the molecule's circulating half-life, allowing less frequent dosing while sustaining receptor engagement long enough to drive meaningful lymphocyte expansion. This class of agent is generally described as promoting immune reconstitution rather than directly killing target cells, distinguishing it from cytotoxic or checkpoint-based immunotherapies. Its relevance spans oncology, infectious disease, and post-transplant immune recovery, wherever restoring a functional and diverse T-cell repertoire is a clinical goal.